Heart Failure

Low-density lipoprotein cholesterol value below 88 mg/dL was associated with heightened mortality, highlighting the need for more liberal cholesterol targets in this population.

The innovative neonatal cardiac progenitor cell therapy is designed to repair heart tissue in patients with heart failure with preserved ejection fraction (HFpEF).

This subset of heart failure requires unique therapeutic considerations.

Vutrisiran becomes the first and only therapeutic FDA-approved to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.

Pharmacists can optimize management of this condition with intravenous iron therapy guidance.

The new indication would include adults with heart failure with a left ventricular ejection fraction (LVEF) of 40% or higher, such as mildly reduced or preserved LVEF.

If approved, vutrisiran would be the first FDA-approved therapy to treat both the polyneuropathy and cardiomyopathy aspects of transthyretin amyloidosis (ATTR).

Pharmacists also educate, advocate, and ensure patients with heart failure with reduced ejection fraction (HFrEF) and anemia are receiving the appropriate regimens.

Compared with other indicators of cardiovascular risk, the ratio of non-high-density lipoprotein cholesterol (HDL-C) to normal HDL-C had a stronger association with the risk of hypertension and heart disease.

The initiative will provide information about care models for specialists and clinical teams to improve patient outcomes in heart failure.

Duchenne muscular dystrophy is an incurable neuromuscular disorder that can lead to cardiomyopathy, resulting in heart failure.

The pumps can now be used to treat pediatric patients who have symptomatic acute decompensated heart failure and cardiogenic shock.

Within the Veterans Health Administration System, primary care pharmacists are embedded in primary care panels and work alongside primary care physicians and nurses to optimize medication management for patients.

This is the first trial that tested the effect of any medication on major heart failure outcomes in patients with HFpEF and obesity, according to investigators.

These therapies represent an encouraging advancement in cardiovascular care.

Higher doses of β-blockers are associated with better clinical outcomes in patient with heart failure.

Current guidelines recommend a backbone of SLGT2 therapy in patients with HFpEF who have no contraindications.

AI-enabled remote cardiac monitoring offers continuous data on heart activity, allowing for the early detection of arrhythmias, optimized treatment timing, and improved sleep-related heart health management.

New insights into heart failure risks in Native American communities are highlighting the need to address social determinants of health.

Women's health extends beyond reproductive health, yet much of the research in women's health focuses on these "below the belt" health issues, despite data showing that women disproportionately suffer from certain health conditions, such as heart failure.

Investigators compare the impact of semaglutide for preserved ejection fraction and reduced ejection fraction, which both have different causes and responses to treatment.

Non-steroidal mineralocorticoid receptor antagonist, finerenone, demonstrated improved efficacy compared with existing steroidal treatment for patients.

Tirzepatide demonstrates statistically significant improvements in adult patients who have heart failure with preserved ejection fraction and obesity.

Investigators compared the criteria for eligibility in the VICTORIA trial with guideline and label criterion, finding a wider than expected population with heart failure were eligible for vericiguat therapy.

Consumer-wearable devices can monitor treatment response and provide continuous health data for patients with heart disease and atrial fibrillation.

The RECTIFIER framework was able to screen patients with heart failure more accurately and with a cheaper cost than traditional screening methods.

This narrative review dispels the long-held belief that reduction in salt intake leads to better health outcomes in patients with heart failure.

Semaglutide was found to have effects on glycemia, inflammation, and heart failure outcomes in sub analyses.

Small steps can accumulate and have a big impact on patients’ lives

The finding did not reach statistical significance in the primary composite endpoint.